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Systemic sclerosis is a multisystem autoimmune disorder that involves the gastrointestinal tract 
in over 90% of patients. This involvement can extend from the mouth to the anus, with the 
oesophagus and anorectum being most frequently affected. Gut complications result in a 
plethora of presentations that impair oral intake and faecal continence and, consequently, have 
an adverse effect on patient quality of life, resulting in referral to gastroenterologists. The 
cornerstones of gastrointestinal symptom management are to optimize symptom relief and 
monitor for complications, in particular anaemia and malabsorption. Early intervention in 
patients who develop these complications is critical to minimize disease progression and 
improve prognosis. In the future, enhanced therapeutic strategies should be developed, based 
on an improved understanding of the intestinal pathophysiology of systemic sclerosis. This 
Review will describe the most commonly occurring clinical scenarios of gastrointestinal 
involvement in patients with systemic sclerosis as they present to the gastroenterologist, with 
recommendations for the suggested assessment protocol and therapy in each situation.  
 
Key points 
 Gut involvement in systemic sclerosis occurs more commonly in the diffuse than the 
limited cutaneous variant 
 Oesophageal involvement is the most common gastrointestinal manifestation of systemic 
sclerosis, with severe reflux disease and dysphagia the main presentations 
 When treating small intestinal bacterial overgrowth in patients with systemic sclerosis, 
effectiveness of treatment and decisions about cyclical courses of antibiotic are best 
assessed by symptoms rather than breath testing 
 Malnutrition in patients with systemic sclerosis is associated with more aggressive 
disease progression, and the risk of developing malnutrition is related to both gut and 
extraintestinal factors 
 Faecal incontinence in systemic sclerosis is related to anal sphincter atrophy and is poorly 
responsive in the long-term to sacral neuromodulation 
 
Systemic sclerosis is a chronic autoimmune-mediated connective tissue disorder. Although the 
aetiology of the disease remains undetermined, systemic sclerosis is characterized by fibrosis 
and proliferative vascular lesions of the skin and internal organs. Prevalence of the disease in 
Europe and the USA is estimated at 8–30 per 100,000 people, with an annual incidence of 1–2 
per 100,000 people[1-3]. Incidence of systemic sclerosis is twice as frequent in black compared 
with white populations, and the disease is between twofold and fourfold more common in 
women than in men; peak age of disease onset is 30–50 years[2,3]. Systemic sclerosis is 
classified as either diffuse or limited cutaneous disease, based on the extent of skin 
involvement, with limited systemic sclerosis accounting for ~80% of diagnoses[4]. Patients with 
limited systemic sclerosis have skin thickening (scleroderma) only distal to the elbows and 
knees, but the face can be affected in those with diffuse or limited disease. This classification 
also defines the organ involvement, autoantibody profile  and clinical progression of the 
disease[5,6] Diffuse disease is characterised by having positive ScL70, early and rapid organ 
involvement and with a poor prognosis. Limited systemic sclerosis is characterised by positive 
anti-centromere antibodies, slow progression, visceral involvement later in the disease course 
and a better prognosis. Involvement of the gastrointestinal tract can be found in either form, 
but is more common in patients with diffuse disease[6]. Gastrointestinal symptoms are seen in 
up to 90% of all patients, and are the presenting feature of disease in 10% of individuals[7]. 
Gastrointestinal involvement is the leading cause of morbidity and third most common cause 
of mortality in patients with systemic sclerosis, with cardiopulmonary and renal involvement 




Vascular endothelial hyper-reactivity manifested as recurrent episodes of vasoconstriction, and 
reperfusion has been hypothesized to be the initial pathological event in the development of 
systemic sclerosis [8]. Sequential histological studies of enteric smooth muscles from patients 
with systemic sclerosis suggest that the initial trigger for this vascular instability is autonomic 
axonal degeneration, specifically sympathetic overactivity[9,10]. Alternatively, the initiating 
event has also been hypothesized to be autoimmune related, on the basis of 
immunohistochemical studies showing the presence of circulating IgG autoantibodies against 
myenteric neurons in many patients with systemic sclerosis [11]. Currently available data 
support a combination of the autoimmune and autonomic aetiology hypotheses, with the 
identification that circulating IgG autoantibodies are capable of disrupting intestinal 
myoelectrical function [11,12]. Specifically, patients with systemic sclerosis express antibodies 
to the muscarinic acetylcholine receptor M3, which is critical for the control of intestinal 
peristalsis by the enteric nervous system[12,13]. Patients with more severe gastrointestinal 
phenotypes have increased expression of these antibodies, supporting a causal link between 
antibody levels and gastrointestinal systemic sclerosis features[13]. 
 
Whatever the aetiology of the disease, vascular instability is thought to progress to tissue 
ischaemia and subsequent defective immunity and tissue repair. Tissue repair in patients with 
systemic sclerosis is characterized by excessive collagen and collagen matrix deposition, 
resulting in fibrotic replacement of tissue in the skin and internal organs, including in the 
gastrointestinal tract[14]. Fibrosis involves both the gut smooth muscle and the smooth muscle 
of the gastrointestinal vasculature[15]. This fibrotic infiltration in the gut  results in dysmotility 
and delayed transit time, which can affect any gastrointestinal region from the oral cavity to 
the anus[8,16,17]. 
 
Gut involvement can progress slowly or rapidly  [18,19]. However, several studies have failed to 
show any correlation between gastrointestinal symptoms and severity of physiological 
compromise in systemic sclerosis[8,10]. There also seems to be no correlation between patient-
reported severity of gut symptoms and degree of morbidity of systemic sclerosis[20]. Severe 
gastrointestinal involvement, especially small bowel involvement presenting with 
malabsorption and dysmotility, is associated with increased mortality in some series[4,21]. This 
finding emphasises the importance of early and continuous monitoring of gastrointestinal tract 
involvement in patients with systemic sclerosis to avoid these severe syndromes of small bowel 
failure[22]. Optimal monitoring assessments and emerging potential therapies will be detailed 
in this Review, which will be structured around presentation symptoms and syndromes, rather 
than anatomical location, so as to have the greatest utility to the clinician seeing these patients. 
 
Dysphagia 
Although oesophageal dysmotility is the most common gastrointestinal manifestation of 
systemic sclerosis[18,23,24], it is vital to consider that dysphagia might be caused by a GERD-
related stricture (discussed later), and hence an upper gastrointestinal endoscopy might be 
appropriate to exclude this possibility. In turn, however, the absence of oesophageal symptoms 
does not necessarily exclude oesophageal involvement since physiological change may precede 
symptom development [20,25]. Whether the prevalence and severity of oesophageal dysmotility 
is related to the extent or severity of cutaneous systemic sclerosis involvement is unclear[26, 27]. 
Oesophageal manometry has superseded scintigraphy and barium radiography as a diagnostic 
modality since it is more reproducible, more interpretable and more available. High-resolution 
manometry might reveal more about the pathophysiology of dysphagia in systemic sclerosis, 
as our understanding of this methodology improves, given its ability to demonstrate subtle 
topographic change not necessarily picked up by conventional manometry. The characteristic 
motility abnormalities in patients with systemic sclerosis are: reduced (or absent) lower 
oesophageal sphincter pressure; ineffective oesophageal body peristalsis (especially in the 
distal oesophagus); and incoordination of peristaltic and lower oesophageal sphincter 
function[8,15,27,28,29]. Pharyngeal and proximal oesophageal motility is normal in systemic 
sclerosis [30]. This may reflect the somatic innervation of the proximal oesophagus, which is 
relatively spared compared to visceral innervation.   
 
To date, no pharmacological intervention has been shown to influence the development of the 
oesophageal complications of systemic sclerosis  and, consequently, treatment focuses on 
symptomatic management with prokinetic agents [22]. Prokinetic agents stimulate gut peristalsis 
through a direct receptor mechanism on enterocytes, as opposed to laxatives which tend to have 
a non-specific mucosal contact action. Considerable data exists on the acute manometric effects 
of prokinetics such as metoclopramide, erythromycin, bethanechol, buspirone and 
domperidone, and these studies have been reviewed elsewhere[26], but no formal studies have 
been published on the use of these agents in clinical practice. Prucalopride might have a role 
as a prokinetic, given its mechanism of increasing cholinergic tone in the gut and hence 
enhancing peristalsis in upper and lower gastrointestinal tract[31, 32]. In any event, prokinetic 
agents probably have no effect in advanced systemic sclerosis when smooth muscle atrophy 
would preclude their being beneficial. In terms of non-pharmacological therapies, a study of 
patients with early systemic sclerosis suggested a role for low-frequency electrical acupuncture 
stimulation to improve dysphagia[33]. In brief, the technique involves insertion of stainless steel 
acupuncture needles in designated points and attached to an electrical stimulator at variable 
frequencies, the intensity being adjusted to produce local muscle contractions without pain and 
discomfort. The uncontrolled study included 34 patients with systemic sclerosis and showed 
modest clinical benefits in tandem with modest changes in inflammatory biopsies from 
cutaneous biopsy pre- vs post-treatment. Treatment duration varied in studies from 3 months 
to 9 years. Transcutaneous electrical nerve stimulation (TENS) has not shown efficacy in 
patients with more advanced disease [34]. High-frequency TENS applied during oesophageal 
manometry showed no change in any motility parameters. There is no data on low frequency 




The manometric features described earlier demonstrate a strong predisposition in patients with 
systemic sclerosis to pathological GERD; over three-quarters of patients with systemic 
sclerosis have erosive reflux changes in the oesophagus[35], and degree of erosive correlates 
with change and severity of dysmotility [36]. As such, monitoring of patients with systemic 
sclerosis by simultaneous recording of oesophageal pH and manometry has been 
recommended, regardless of the presence or absence of reflux symptoms[37]. Fifty percent of 
patients with systemic sclerosis have delayed gastric emptying[15,38, 54] which also predisposes 
to GERD. The severity and chronicity of GERD in patients with systemic sclerosis results in 
high rates of stricturing and the development of Barrett oesophagus in 40%[39]. 
 
Conservative therapy of GERD symptoms (lifestyle modification, postural assistance and 
dietary modification) has not been formally studied in patients with systemic sclerosis, but 
given the severity of physiological disturbance in these individuals such treatments are rarely 
effective in isolation[39,40]. Nevertheless, eating small meals, avoiding meals shortly before 
recumbence, reducing fat intake and ceasing smoking are all reasonable approaches[26,40]. PPIs 
are the core of GERD maintenance therapy, and might need to be used in double or even 
quadruple doses[41,42]. Given the increasingly well-recognized adverse effects of chronic PPI 
use[43] and the need for chronic therapy in patients with systemic sclerosis, counselling patients 
at initiation of treatment is important. Adverse effects relevant to patients with systemic 
sclerosis are the association of PPIs with osteopaenia, intestinal infection (including small 
intestinal bacterial overgrowth (SIBO)) and interaction with antiplatelet therapies. Based on a 
comparator study with the 5-hydroxytrypamine receptor 2 (also known as serotonin receptor 
2) agonist cimetidine, use of antacids is not supported in systemic sclerosis, but provided that 
aluminium-containing agents (which can cause constipation) are avoided, they might  be a low-
risk alternative. The efficacy of adding 5-hydroxytrypamine receptor 2 agonists to PPIs 
improve GERD symptoms has not been studied in patients with systemic sclerosis, yet benefit 
is minimal in patients with GERD who do not have systemic sclerosis[44]. More aggressive 
modalities such as endoscopic or laparoscopic antireflux procedures are also unreported in 
systemic sclerosis and are best avoided as they are likely to be complicated by dysphagia, given 
the known severe dysmotility in these patients[8,15]. 
 
A key focus of GERD therapy is to avoid progression to more complex manifestations such as 
oesophageal strictures or Barrett oesophagus. Endoscopic dilatation is indicated in the ~30% 
of patients with systemic sclerosis who develop strictures which will manifest as progressive 
dysphagia. [45], in addition to optimizing PPI therapy to minimize stricture recurrence. 
Prospective studies of Barrett oesophagus in patients with systemic sclerosis showed an annual 
3% rate of progression to high-grade dysplasia and 0.7% incidence of oesophageal 
adenocarcinoma[46,47]. Discussion of the frequency of screening for Barrett oesophagus is 
beyond the scope of this Review, but the high incidence  of high-grade dysplasia in patients 
with systemic sclerosis mandates frequent endoscopic monitoring. There is no guidance on the 
frequency of such monitoring, but it should be influenced by multi-disciplinary assessment of 
severity of symptoms, degree and rate of histological change. 
 
An emerging important complication of GERD seems to be the role of micro-aspiration of 
gastric content as a driver of interstitial lung disease. Initial data in an animal model [48] showed 
that gastric content introduced into the lung caused a parenchymal fibrotic reaction. This 
finding has been supplemented with data in patients with systemic sclerosis[49] correlating 
increased degree of lung fibrosis with more frequent reflux episodes and greater proximal 
extent of refluxate. The relationship between reflux and development of pulmonary 
involvement is equivocal: 50% of patients with systemic sclerosis with severe reflux associated 
with lung disease risk were asymptomatic from the oesophageal perspective, and progression 
of lung disease was not associated with progressive hypomotility[50,51]. There is, as yet, no trial 
data showing improvement in the lung function of patients with systemic sclerosis after 
aggressive GERD management. However the prospective cohort data on progression of 
oesophageal motility and pulmonary pathophysiology supports the use of PPIs with add-on  
prokinetic agents, even in asymptomatic patients [50]. This view has been supported by the 
identification of a novel histological form of lung disease, known as centrilobular fibrosis 
which is seen especially in those patients with systemic sclerosis who also have severe GERD 
[51]. 
 
Vomiting and abdominal pain 
Delayed gastric emptying is seen in ~50% of  patients with systemic sclerosis [52, 53]. This 
functional delay seems to relate to both structural changes (reduced gastric size)[54] and slowing 
of gastric electrical activity associated with the autonomic nerve [37,55]. The typical 
gastroparesis symptoms of abdominal bloating, pain, early satiety and vomiting are more 
commonly reported in diffuse rather than limited cutaneous systemic sclerosis[56]. None of 
these features are unique to systemic sclerosis, as they are also observed in functional dyspepsia 
as well as other causes of gastroparesis such as diabetes mellitus. As such, these symptoms  
cannot be recommended as clinically useful for diagnosis of systemic sclerosis or monitoring 
of the disease. This is especially disappointing  because the correlation between symptom 
burden and objective abnormalities is poor[56], leaving no widely accepted gold standard to 
measure outcome.  
 
As with GERD management, there is no evidence specific for patients with systemic sclerosis 
in support of lifestyle and dietary therapies to manage delayed gastric emptying. Low-residue 
diets (which reduce stool frequency and liquidity by reducing fibre and gut stimulants such as 
dairy) and vitamin supplementation have been recommended on an empirical basis[8]. Equally 
disappointing is the lack of efficacy of prokinetic and antiemetic drugs in patients with systemic 
sclerosis. With regards to prokinetics, erythromycin (as opposed to domperidone) has been 
studied in this patient group [57], but accelerates gastric emptying at a dose (200 mg) while also 
inhibiting small bowel motility [58]. Symptom response data beyond 33 weeks for erythromycin 
is lacking, and the drug is most effective in early disease, before smooth muscle atrophy and 
fibrosis set in[57]. A consensus guideline of the management of gastroparesis in general 
suggested that the liquid formulation of metoclopramide can be considered if no neurological 
or electrocardiographic adverse effects develop, although there is no specific evidence in SSc-
associated gastroparesis [59]. Octreotide does not seem to have an effect on gastric emptying or 
gastroparetic symptoms[60]. A placebo-controlled crossover study of infusion with the gastric-
derived prokinetic hormone ghrelin[61] in 10 patients with systemic sclerosis showed an 
acceleration of gastric emptying (53 minutes saline vs 43 minutes ghrelin) [62], raising the 
potential for ghrelin analogues as therapy. Jejunal feeding can be considered in situations in 
which there is symptomatic delay in gastric emptying in the presence of normal small bowel 
transit[63]: this treatment and parenteral nutrition will be discussed in detail later. A single-
centre study of transcutaneous electrical nerve stimulation has shown short-term (two weeks) 
efficacy in improving  gastroparesis symptoms associated with systemic sclerosis [64]. Surgical 
procedures such as venting gastrectomy or antrectomy are associated with major long-term 
complications[65] and should only be considered in the most extreme of situations such as 
intractable vomiting, anorexia and profound progressive weight loss [8].  
 
Small intestinal bacterial overgrowth 
The clinical symptoms of SIBO are abdominal bloating, flatulence, early satiety, post-prandial 
nausea and, occasionally, diarrhoea[20,26,40]. Disturbances of small intestinal motility and 
immunity can be compounded by hypochlorhydria secondary to PPI usage and hence 
predispose to migration and colonization of the small intestine by colonic microbiota [66,67]. If 
not corrected SIBO can result in malnutrition, so treatment is essential, not just from the 
symptom-relief perspective. Hydrogen breath testing (after either a glucose or lactulose meal) 
is widely used as the clinical standard for diagnosis of SIBO, but analyses in the past few 
years[68,69] have shown that the specificity and sensitivity of such testing is no better than 68 
and 44% respectively. However, the intrusiveness and comparative expense of the research 
standard, upper gastrointestinal endoscopy with culture of duodenal aspirate[67], makes breath 
testing the most widely used, and in the author’s opinion the most valid, modality for diagnosis. 
The alternative to testing for SIBO is to treat empirically with broad-spectrum antibiotics 
(against both aerobic and anaerobic strains) to modify the microbiota sufficiently to result in 
symptomatic improvement, rather than attempting to eradicate the specific strain[70].  
 
Antibiotic therapy is as effective at improving symptoms in patients with systemic sclerosis 
and SIBO[71] as it is in patients with IBS [69]. A meta-analysis[72] of antibiotic therapy for SIBO 
(caused by a variety of aetiologies beyond just SSc) published in 2013  identified SIBO 
symptom improvement in approximately two-thirds of patients, with no statistically significant 
advantage of any one agent over another. Antibiotics used in the treatment of SIBO in the 
analysed trials include amoxicillin, ciprofloxacin (and other quinolones), doxycycline (and 
other tetracyclines), metronidazole, rifaximin (and other minimally absorbable antibiotics) and 
trimethoprim–sulfamethoxazole. The outcome of the meta-analysis was to use any of these 
antibiotics for 10–14 days and to monitor outcome by symptoms rather than breath testing 
given the poor sensitivity of the latter [72]. In the clinical context of systemic sclerosis, in which 
SIBO can be recurrent due to the underlying pathophysiology in the gut, some experts argue in 
favour of cyclical courses of antibiotic for patients with recurrent proven SIBO (by culture of 
endoscopically obtained duodenal aspirate) — for example, 10–14 days treatment every month, 
rotating between the antibiotics listed previously to protect against the development of 
antibiotic resistance [20,72,73]. An alternative treatment strategy in this situation is to give a 
probiotic rather than antibiotic when the initial course of antibiotic is withdrawn, although there 
is no clear evidence to recommend any specific product[74]. Probiotic treatment is supported by 
a small body of clinical trial data in idiopathic SIBO[75] as well as SIBO associated with 
systemic sclerosis[76], but definitive controlled trials are needed before such an approach can 
be unequivocally advocated. 
 
Malnutrition 
Malnutrition in patients with systemic sclerosis is usually multifactorial in origin. Oral food 
intake is often reduced as a result of the persistent and debilitating symptoms of nausea, 
vomiting and early satiety caused by gut dysmotility, and SIBO can cause maldigestion and 
malabsorption of specific nutrients. The basic assessments suggested by an expert USA panel 
comprised full blood count, haemoglobin, vitamin A, folic acid, ferritin and vitamin B12. In 
addition, extraintestinal contributors to malnutrition are often present in patients with systemic 
sclerosis: perioral sclerosis means that patients tend to eat a low-residue diet with decreased 
mineral and vitamin intake due to mechanical and pain factors when trying to eat fruit and 
vegetables; intake of nutrients  is often exacerbated by oesophageal dysmotility. In addition, 
finger contractures can make preparing and eating meals arduous. Finally, low mood and 
adverse effects of concomitant therapy (such as calcium channel antagonists, prostaglandin 
derivatives, immune-suppressants and opioids) can reduce appetite[20, 77]. 
 
Malnutrition develops insidiously and so the correct choice of screening modality is unclear. 
A study using the malnutrition universal screening tool (MUST)[78] identified that 28% of a 
cohort of 586 systemic sclerosis patients in Canada were at medium or high risk of malnutrition 
(MUST scores of 1 and ≥2, respectively) [79]. Increased risk  was associated with the degree of 
gastrointestinal symptomatology assessed by trial-specific questionnaire, shorter disease 
duration and overall systemic sclerosis disease severity (gauged by physician rating) [79]. Thus, 
both gut and extraintestinal factors predict the risk of developing malnutrition. Given that 
malnutrition is associated with more-aggressive disease progression [73,77], screening for 
malnutrition is therefore recommended in all patients with systemic sclerosis. Whether this 
association is causal remains to be determined by suitably designed prospective cohort studies. 
This screening should be considered with the MUST tool, a gastrointestinal symptom 
assessment (using a questionnaire such as the University of California, Los Angeles 
Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 
instrument, discussed in detail later [80]) and serology comprising full blood count, haematinics, 
and levels of serum carotene and prealbumin[40,74,77]. Such screening is supported by the 
observation that nutritional treatment improves nutritional status[81] and, hopefully, in turn will 
improve survival; however, prospective long-term studies are required to confirm this 
hypothesis.  
 
The key to managing the patients with malnourishment related to systemic sclerosis is to have 
a framework for practice, underpinned by close multidisciplinary cooperation between 
gastrointestinal and rheumatological teams[74, 77]. In the author’s opinion, if present, SIBO 
should be treated first. In addition, gastrointestinal radiology to exclude chronic intestinal 
pseudo-obstruction (CIPO, discussed in more detail later) is recommended; if there is gut 
dilatation suggestive of CIPO then a trial of prokinetic therapy is appropriate. 
 
If the patient remains malnourished or symptomatic despite these medical therapies then they 
might need to be considered for enteral nutrition[77], either by temporary transnasal or more 
permanent endoscopic tube insertion. On the basis that gastroparesis can be severe in patients 
with systemic sclerosis, the enteral feed is preferably jejunal rather than gastric[22,77]. If enteral 
feeding is not practicable or successful and malnutrition continues, consideration of parenteral 
feeding is appropriate[82]. Despite the well-recognized complications of this approach, which 
include deterioration of liver function, catheter sepsis and venous thrombosis, the benefits in 
terms of weight gain and quality of life of home parenteral feeding have been established in 
patients with systemic sclerosis [82]. Additionally, patients with systemic sclerosis are not at 
higher risk of these complications than patients with intestinal failure secondary to other 
causes[22,82]. 
 Chronic intestinal pseudo-obstruction 
CIPO is characterized by clinical and radiological evidence of chronic episodic intestinal 
obstruction in the absence of a mechanical lesion[83]; it occurs as a result of a visceral myopathy 
or neuropathy and can be primary or, more commonly, secondary to diseases such as systemic 
sclerosis[84]. As there is no mechanical lesion, a critical goal of treatment is to avoid surgery, 
which by definition cannot be curative [83]. Although a wealth of data exists about the natural 
history and poor prognosis of CIPO in general[83,84,85], only one case–control series on patients 
with systemic sclerosis hospitalized with CIPO has been published[86]. Of 64 cases, a high 
proportion (9%) underwent surgical resection and an even larger proportion (16%) died. One-
quarter of the 64 patients were given home parenteral nutrition. Mortality in this case–control 
series was associated with malnutrition at admission (reinforcing the importance of screening 
and treating this gastrointestinal complication of systemic sclerosis) and was higher in men 
than in women [86]. 
 
First-line therapy for acute CIPO is to rehydrate the patient, establish analgesia (using 
paracetamol and non-steroidals, preferably avoiding opioids that tend to exacerbate intestinal 
dysmotility) and decompress the bowel by nasogastric intubation. Addressing nutritional needs 
early on is also important while waiting for CIPO symptoms to abate. Gut prokinetic agents 
can help in this regard, whether or not they are being used in the chronic setting[87,88]. As 
discussed earlier, metoclopramide and domperidone are often of little value. Erythromycin at 
doses of 1.5–2 g per day can be of benefit in some patients with CIPO, including when CIPO 
is secondary to systemic sclerosis[87]. Intravenous neostigmine might help abort an episode of 
pseudo-obstruction, but cardiac and cholinomimetic adverse effects might preclude use in 
patients who are frail[89]. Subcutaneous octreotide, a somatostatin analogue, has proved 
beneficial in several series of patients with systemic sclerosis with CIPO in terms of improving 
gut motility and alleviating symptoms [90,91,92]. Dosing commences at 50 μg twice a day and 
can be increased to a maximum of 200 μg per day according to treatment response[90,91]. A 
combination of oral erythromycin and subcutaneous octreotide has been suggested[58], but as 
the latter seems to delay gastric emptying caution might be needed in patients with systemic 
sclerosis and a combination of CIPO and gastroparesis[58]. A newer long-acting octreotide 
preparation could be a better tolerated alternative to the combination of erythromycin and daily 
subcutaneous octreotide for prevention of relapse [92]. Finally, prucalopride has been shown to 
reduce the frequency of relapse of patients with CIPO, including those with CIPO related to 
systemic sclerosis, in a 1-year placebo-controlled study[88].  
 
Anaemia  
Anaemia in systemic sclerosis is often the anaemia of chronic illness[93], and can be exacerbated 
by the presence of major systemic sclerosis complications such as renal impairment and 
pulmonary hypertension[94]. Anaemia can also occur as part of the malnutrition associated with 
SIBO and systemic sclerosis [77]. Gastric antral vascular ectasia (GAVE) is a rare complication 
of systemic sclerosis (affecting 1–5% of patients with systemic sclerosis[95,96]) that can cause 
anaemia with or without overt gastrointestinal bleeding. Although GAVE has endoscopically 
characteristic appearances (‘watermelon stomach’ created by stripes of ectatic vasculature 
amongst the oedematous gastric mucosa, the condition is defined histologically by mucosal 
capillary dilatation with fibrin thrombi, foveolar epithelial changes and fibromuscular 
hyperplasia[97]. GAVE is most prevalent in early diffuse cutaneous systemic sclerosis, 
characterised by rapid skin progression, and a distinct antibody profile (anti-RNA polymerase 
III positivity) [97].  
 
Management of GAVE in systemic sclerosis is conservative in the first instance, with iron 
supplementation and monitoring of haemoglobin levels to minimize the duration of therapy, 
which can exacerbate constipation[96]. Endoscopic therapy with a neodymium-doped ytrrium 
aluminium garnet (Nd:YAG) laser or argon plasma coagulation is indicated if oral iron 
supplementation fails[98]. Efficacy is similar with both endoscopic treatments (about 90%) but 
multiple treatment sessions are often required with either modality[99,100,101]. However, argon 
plasma coagulation is generally preferred due to its lower cost and reduced risk of 
complications, specifically haemorrhage and need for surgery [101].  
 
In refractory cases in which expert endoscopy is available, evidence from individual series 
support the use of endoscopic band ligation[102], sclerotherapy[103] and cryotherapy[104] for the 
management of GAVE associated with systemic sclerosis. In cases refractory to these 
endoscopy techniques intravenous cyclophosphamide has been used in a series of three patients 
[105] as well as surgical antrectomy[106]. Whilst effective, these therapies are associated with 
morbidity and a mortality of approximately 7%. In a randomized trial, high-dose chemotherapy 
followed by autologous haematopoietic stem cell transplantation (HSCT) has been shown to 
be superior to cyclophosphamide in improving skin and lung function as well as quality of life 
in patients with systemic sclerosis[107], and a report published in 2015 showing a benefit for 
HSCT in patients with systemic sclerosis and GAVE  raises the possibility of curative  therapy 
for this gastrointestinal complication[108]   
 
Constipation 
Altered colonic physiology is seen in between 20–50% of patients with systemic sclerosis, and 
unlike upper gut involvement this condition is often asymptomatic [18,26,77]. Progressive colonic 
smooth muscle atrophy results in diminished or absent peristalsis[109], markedly delayed 
colonic transit[110] and, rarely, colonic pseudo-obstruction [91]. Occasionally systemic sclerosis 
can result in loss of colonic compliance and even stricturing [111,112]. In view of these 
impairments of colonic physiology, and the possibility of common coincidental colonic disease 
(such as diverticulosis and neoplasia), structurally assessing the colon (endoscopy or radiology) 
in a new presentation of constipation is important in patients with systemic sclerosis.  
 
Because slow transit is a frequent accompaniment to systemic-sclerosis-associated 
constipation, a high dietary fibre intake is likely to be poorly effective and is associated with 
frequent bloating and flatulence[113,114]. Optimizing liquid intake can be difficult, especially if 
the patient has renal involvement. Similarly, stimulant laxatives (such as senna or bisacodyl) 
are preferred over macrogol osmotic laxatives in this situation since they cause electrolyte loss 
[114]. Lactulose can be effective, but only usually for 1-3 months since bacterial catabolism of 
the drug develops; the drug is also associated with poor tolerability and the need for dose 
escalation[40,113]. In uncontrolled single-centre series, a variety of prokinetic drugs have been 
shown to improve colonic motility (and to a lesser extent symptoms) in systemic sclerosis: 
metoclopramide 20-30mg per day [109], domperidone (maximum daily dose currently is 30 mg 
per day in divided doses)[8] and prucalopride once a day (2 mg in all patients except over 65 
year olds, in whom the dose is reduced to 1 mg)[32] have been shown to improve colonic 
motility, whereas erythromycin[115] and octreotide[8] seemingly have efficacy only on small 
intestinal motility. If successful, long-term use of prokinetic agents is a reasonable option since 
the drugs seem well tolerated I the long-term with no evidence of tachyphylaxis [113,114]. 
Surgical resection (with or without stoma formation) is a poor option for patients with systemic 
sclerosis given the potential for skin complications (poor wound healing, stoma prolapse or 
retraction) and prolonged ileus, but might be required in extreme cases with perforation or 
those who are refractory to drugs[116,117]. In those patients with systemic sclerosis and 
constipation refractive to drugs, less radical options such as colonic pacing (in which an 
electrical impuls generator is implanted to stimulate the right colon) [118] or sacral nerve 
stimulation[119] are appealing, but have not been studied specifically in patients with systemic 
sclerosis. 
 
Air in the bowel wall (pneumatosis cystoides intestinalis) is a rare manifestation of systemic 
sclerosis in the colon [120]. This condition is usually inconsequential with no manifestation of 
symptoms, and is generally picked up by chance during abdominal radiology. On very rare 




Diarrhoea in a patient with systemic sclerosis might indicate alterations in upper gut function, 
not just colonic involvement. SIBO is an important consideration and evidence suggests that 
this condition can be identified in a patient with diarrhoea by the presence of raised faecal 
calprotectin levels [121]. Additional aspects of small bowel involvement can also contribute to 
a steatorrhoea-like presentation in systemic sclerosis[37,73,77,122], including: intestinal ischaemia 
secondary to mesenteric vasculopathy; impaired lymphatic drainage secondary to fibrosis; loss 
of small intestinal surface area and function secondary to fibrotic infiltration; bile acid 
malabsorption independent of SIBO; fructose intolerance; and amyloidosis as a consequence 
of chronic inflammation. 
 
For patients with systemic sclerosis and diarrhoea, the primary goal is to treat the underlying 
causes of intestinal dysfunction as listed previously, with consideration for the use of 
antibiotics for SIBO and bile acid sequestrants for bile acid malabsorption[122]. If all of these 
causes of intestinal dysfunction have been excluded or treated and diarrhoea continues, using 
judiciously titrated low doses of loperamide is reasonable, but caution should be exercised to 
avoid precipitation of severe constipation and possibly even a bout of CIPO symptoms[22,114]. 
A diet low in FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides 
And Polyols), which reduces the osmotic and fermentable substrate in the gut, is useful in 
improving diarrhoea in idiopathic and organic disease[123], and could have a role in treating 
diarrhoea in patients with systemic sclerosis although this indication has never been studied. 
 
Faecal incontinence 
As many as 20% of patients with systemic sclerosis report faecal incontinence[124], which leads 
to major effects on quality of life[125,126]. The underlying pathology is atrophy and fibrosis of 
the smooth muscle of the internal anal sphincter[127] with excess distensibility of the anal 
canal[128]. The most common presentation with sphincter involvement is passive faecal 
incontinence or soiling[129]. The alternative presentation of anorectal involvement in systemic 
sclerosis is rectal prolapse[22,77,130], which can in turn exacerbate faecal soiling as the sphincter 
is held open by the prolapse. Rectal prolapse in patients with systemic sclerosis results from 
accumulation of collagen in the rectum, which causes reduced rectal compliance and 
subsequent straining[131]. Anorectal involvement is characterized by reduced resting anal tone, 
reduced rectal balloon distensibility and an attenuated rectoanal inhibitory reflex[129,130,132]. 
 
When stools are loose (Bristol type 6 or 7) augmenting fibre intake can improve symptoms[129], 
yet otherwise this dietary modification is of little benefit and can even cause abdominal 
bloating. Antidiarrhoeals, specifically loperamide, might improve diarrhoea, but need to be 
used carefully to avoid exacerbating constipation and straining, which in turn is associated with 
increased risk of prolapse[22,133]. Suppositories can be used to optimize rectal evacuation 
without straining in this situation[22,113]. Pelvic floor biofeedback has never been studied in 
patients with systemic sclerosis but does warrant consideration in this population, given the 
nature of anorectal involvement and the known potential for biofeedback therapies in treating 
Raynaud phenomenon in systemic sclerosis[134]. 
 
Sacral nerve stimulation has been studied extensively in anorectal dysfunction not related to 
systemic sclerosis and in patients with systemic sclerosis and faecal incontinence in a small 
(n=5) single-centre study with 24 month follow-up [135]. However, a multisite report in a larger 
patient cohort has suggested that although there are no safety concerns associated with the 
technique, the overwhelming majority of patients with systemic sclerosis derive no sustained 
benefit to anorectal function from continued sacral neuromodulation[136]. A randomized 
placebo-controlled study published in 2014 has suggested that posterior tibial nerve stimulation 
could be an alternative effective method of neuromodulation and relief of faecal incontinence 
symptoms in systemic sclerosis[137]. Long-term follow-up of patients treated successfully in 
this study is needed to determine whether symptom relief is maintained. 
  
Given potential tissue healing problems, surgery is best avoided in patients with systemic 
sclerosis and anorectal dysfunction. However, if there is a severe rectal prolapse, resection of 
the rectum and sigmoid colon is the preferred surgical approach to transanal mucosal 
procedures which have a high failure rate related to breakdown of the suture line [131].  
 
Symptom questionnaires 
Gastrointestinal involvement in patients with systemic sclerosis is common and protean in 
manifestation. The emphasis of effective management is on early recognition, accurate 
categorization of regional involvement and prompt treatment to prevent the development of 
severe acute or chronic complications. In particular, avoiding malnutrition is important given 
its association with a worse prognosis. To that end, the central role of a validated and 
reproducible questionnaire for patients with systemic sclerosis has been recognized. Khanna 
and colleagues have pioneered the development of the UCLA SCTC GIT 2.0 instrument to 
address this requirement [80]. This questionnaire is an update of an earlier version, and 
comprises seven subscales: reflux, distention/bloating, diarrhoea, fecal soilage, constipation, 
emotional well-being and social functioning and a total GI score. It has been validated by other 
groups internationally in both limited and diffuse SSc patients, and against measures of 
intestinal motility[20,138] (oesophageal manometry and anorectal physiology). In addition, the 
UCLA SCTC GIT 2.0 instrument also offers a potential standard against which research studies 
can quantify gastrointestinal symptom burden in individuals with systemic sclerosis. The 
instrument has been used in this way to quantify disease in patients with upper and lower gut 
symptoms[127,138]. Allied to a nutrition tool such as  MUST[78], the UCLA SCTC GIT 2.0 is 
important in the symptom assessment of the patient with systemic sclerosis, including patients 
with and without gastrointestinal symptoms. In a complex multisystem disorder such as 
systemic sclerosis, a disease-specific questionnaire is probably of greater value than more 
generic questionnaires[139], even rigorously developed patient-reported instruments such as the 
Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal 
symptom scale[140]. PROMIS has been shown to have construct validity in patients with 
systemic sclerosis, and is increasingly used in idiopathic gastrointestinal disorders including 
inflammatory bowel disease and irritable bowel syndrome [141]. 
 
Summary of disease management  
In patients with systemic sclerosis the gastrointestinal tract is the most commonly affected 
visceral system. Although oesophageal complications have received most recognition and 
study, any region of the gut can be involved. What is clear is that quality of life is reduced in 
patients with systemic sclerosis who develop gastrointestinal complications. 
 
Table 1 summarizes the diagnostic considerations according to symptom presentation when 
managing patients with systemic sclerosis. Owing to the high prevalence of severe reflux 
symptoms in patients with systemic sclerosis, pragmatic, evidence-based patient management 
begins with the use of PPIs to control reflux symptoms and potentially reverse oesophageal 
and pulmonary complications. The second most commonly involved gastrointestinal site in 
systemic sclerosis is the anorectum, and patients should be actively screened for symptoms of 
constipation, diarrhoea and faecal incontinence. Laxative therapy tailored to individual needs 
and combined with toileting and lifestyle advice can successfully treat many patients with 
constipation and minimize the risk of rectal prolapse. Diarrhoea has a variety of treatable causes 
that can be identified with fairly simple investigation. Faecal incontinence is a disabling 
symptom of anorectal involvement in systemic sclerosis and might be amenable to 
neuromodulation therapy. As malnutrition is associated with increased disease severity and a 
poorer prognosis, active screening should be used to identify patients with this symptom and 
to target them for early intervention; screening can be accomplished by simple anthropometric 
measurements (such as BMI, circumferences of mid upper-arm and waist, triceps skin-fold 
thickness) but also by serial observation of the patient and the simple tool of the MUST. The 
key to successful management of this wide array of physically and socially disabling symptoms 
is early identification and symptom control because at the current time no therapy can reverse 
the pathophysiology of systemic sclerosis involvement in the digestive tract. Given the wide 
range of manifestations of systemic sclerosis, there is a preeminent role of the multidisciplinary 
team (MDT) in these patients: key members of the team would include a gastroenterologist, 
rheumatologist, dietitian and radiologist. 
  
Future research directions 
Given the prevalence of gastrointestinal symptoms in systemic sclerosis, a number of avenues 
for future research exist. Current questionnaires should expand beyond assessment of the 
frequency of symptoms to also include symptom severity and the effects on patient quality of 
life. The expansion of these tools would require validation of the new questionnaires in patients 
with limited and diffuse systemic sclerosis. The potential utility of gastrointestinal diagnostics 
(faecal calprotectin levels, selenium homocholic acid taurine (SeHCAT) testing and hydrogen 
breath testing) to identify occult inflammation, bile acid malabsorption and sugar intolerances 
needs exploration in symptomatic and asymptomatic patients with systemic sclerosis. In 
addition, clinical trials of novel gastrointestinal agents such as prokinetic agents (for example, 
prucalopride) or secretagogues (for example, linaclotide and lubiprostone) are required to 
ascertain whether these gut mucosa targeted agents, which act on specific mucosal receptors 
have a particular efficacy in those patient groups. If the results of such trials are positive, these 




Gastrointestinal involvement is the commonest cause of morbidity and third most common 
cause of mortality in patients with systemic sclerosis, affecting especially those patients with 
diffuse rather than limited disease. Oesophageal involvement in the form of severe reflux and 
dysphagia are very common and need treatment to alleviate symptoms and potentially reduce 
pulmonary co-morbidity. Malnutrition needs to be surveyed for and managed actively. 
Constipation and faecal incontinence may coexist; novel drug and neurostimulation 
treatments may offer therapeutic potential. When present diarrhoea may have a variety of 
causes which should be examined for in order to tailor treatment.   
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Figure 1 | Small-intestinal involvement in systemic sclerosis is associated with marked 
physiological changes compared with normal tissue. [Au:Figure title OK? I’ve 
suggested text but please feel free to change as you see fit  -  note  that  the  figure  and  
legend  must  be  understandable  in  isolation  from  the  main  text] The four key 
pathophysiological mechanisms causing gastrointestinal dysfunction in patients with systemic 
sclerosis are: infiltration of immune cells into gut smooth muscle; fibrosis of gut smooth 
muscle; labile vascular tone of the submucosal arterioles and venules; and enteric nervous 
system and smooth muscle dysfunction. ENS, enteric nervous system. 
 
Figure 2 | Gastrointestinal presentations in systemic sclerosis according to anatomical 
location. 
 
Figure 3 | Proposed pathway for screening and managing malnutrition in patients with 
systemic sclerosis. These recommendations are in the opinion of the author. [Au:OK?]  
CIPO, chronic intestinal pseudo-obstruction; GI, gastrointestinal; MDT, multidisciplinary 














Table 1 | Potential differential diagnoses according to symptom presentation [Au:OK?]  
 
Symptom Differential diagnosis Assessment 







Ambulatory pH and 
impedance 





Ambulatory pH and 
impedance 






Hydrogen breath test 





Hydrogen breath test 
 
Abdominal X-ray or CT / 
[Au:Do you mean X-ray 
OR CT or CT or MRI in 
this instance? Or do you 
mean CT and/or MRI? 
Or CT with MRI? Can 
you please clarify for 
other instances in the 
table.] MRI of abdomen 
Weight loss Systemic comorbidity 
(sepsis, drug related) 
Reduced oral intake 




Careful history taking 
 
 
Abdominal radiography or 
CT/MRI of abdomen 





Abdominal X-ray or CT / 
MRI of abdomen 
Diarrhoea Overflow diarrhoea 
SIBO 




Digital rectal examination 
Abdominal X-ray or CT / 
MRI of abdomen 
SeHCAT study 
Serology while on gluten 
Breath test 
Lower gastrointestinal 




Comorbid obstetric injury 
Comorbid diarrhoea 
Endoanal ultrasonography 
and anorectal physiology 
 
CIPO, chronic intestinal pseudo-obstruction; SeHCAT, selenium homocholic acid taurine; 
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